This ppt will give you a clear explanation of pharmacotherapy of obesity. Including importance of lifestyle modification and various drug therapy for obesity and its Risk factors

1. PHARMACOTHERAPY
OF
OBESITY
DURGESH K
II YEAR MBBS
ARUNAI MEDICAL COLLLEGE AND HOSPITALS

3. objectives
P H A R M A C O T H E R A P Y O F O B E S I T Y
INTRODUCTION
1
2
3
GENERAL PRINCIPLES
DRUGS USED FOR OBESITY

4. OBESITY – DRUG THERAPY
• Various drugs approved by FDA
• Should be used along with lifestyle
modifications
GOALS OF THERAPY
MAIN GOALS INCLUDE
•LONG TERM WEIGHT LOSS
•IMPROVEMENT IN OVERALL
HEALTH
P H A R M A C O T H E R A P Y O F O B E S I T Y
4

5. GENERAL PRINCIPLES
5
INITIAL MANAGEMENT
Only lifestyle
modifications OR
combination with drugs
and surgery
APPROACH TO
COMORBIDITIES
Weight related co-
morbidities
1 2
P H A R M A C O T H E R A P Y O F O B E S I T Y

6. CANDIDATES ELIGIBLE FOR DRUG THERAPY
6
• BMI > 30 Kg/m2
• With weight related co morbidities
• Not met with weight loss only with
lifestyle modifications
P H A R M A C O T H E R A P Y O F O B E S I T Y

7. Drugs used for obesity
7
• GLP – 1 agonists
• Dual acting GLP – 1 & GIP receptor agonists
• Altering fat digestion
• Drug combinations
• Sympathomimetics
P H A R M A C O T H E R A P Y O F O B E S I T Y

8. GLP – 1 RECEPTOR AGONISTS
• Glucagon like peptides
• Releases insulin
•Semaglutide & Liraglutide
• First line treatment in Obesity
P H A R M A C O T H E R A P Y O F O B E S I T Y
8

9. GLP – 1 RECEPTOR AGONISTS
SEMAGLUTIDE > LIRAGLUTIDE
 Weekly doses
 Less ADR
C/I : Pregnancy, Pancreatitis and Medullary thyroid
carcinoma
P H A R M A C O T H E R A P Y O F O B E S I T Y
9

11. DRUGS THAT ALTER FAT ABSORPTION
• Orlistat
• Inhibits Pancreatic lipase
• Decreases lipid absorption
P H A R M A C O T H E R A P Y O F O B E S I T Y

12. 12
DRUGS THAT ALTER FAT ABSORPTION
• Decreases absorption of fat soluble vitamins
• ADR
• Boborgyni
• Cramps
• Flatus and fecal incontinence
•Oxalate induced acute kidney injury
• C/I :
• Pregnancy
• Chronic malabsorption
• Cholestasis
• H/O calcium oxalate stones
P H A R M A C O T H E R A P Y O F O B E S I T Y

13. COMBINATION DRUGS
• PHENTERMINE – TOPIRAMATE
• BUPROPION – NALTREXONE
• Cardiovascular risk – Not Recommended
• C/I :
• Pregnancy (Oro-facial clefts) ,
• Hyperthyroidism
• Glaucoma.
• ADR:
• Dry mouth
• Constipation
• Paresthesia
• Dose related psychiatric and cognitive ADR’s
P H A R M A C O T H E R A P Y O F O B E S I T Y
13

14. SYMPATHO MIMETICS
•Phentermine, Diethylpropion
Benzphetamine.
• Early satiety.
• ADR
• Insomnia
• HT
• Dry mouth
• Constipation
•Nervousness
P H A R M A C O T H E R A P Y O F O B E S I T Y
14

15. THERAPIES NOT RECOMMENDED
15
LORCASERINE – OCCURANCE OF CANCER
DIETRY SUPPLEMENTS
•DIET SHOULD BE MONITORED PROPERLY
•GREEN TEA , GUAR GRAM CAN BE SUGGESTED
P H A R M A C O T H E R A P Y O F O B E S I T Y